Shots:
- Novartis has entered into a definitive agreement with Synnovation to acquire Pikavation Therapeutics (Synnovation’s subsidiary) & its portfolio of PI3Kα inhibitor programs, incl. SNV4818, a P-I/II asset for HR+/HER2- metastatic breast cancer & other solid tumors
- As per the deal, Synnovation will receive $2B upfront, & ~$1B in development, regulatory, & commercial milestones, representing the total deal value of ~$3B; closing is expected in the H1’26
- Novartis will assume full responsibility for the development & commercialization of SNV4818 & other PI3Kα inhibitors, while Synnovation will remain independent & retain ownership of its other R&D subsidiaries
Ref: Businesswire| Image: Pikavation Therapeutics | Press Release
Related News: Novartis to Acquire Avidity Biosciences for ~$12B, Boosting its Neuroscience Pipeline
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
